China-based Contract Research Organization (CRO) VIVA Biotech (HKG: 1873) has announced the inauguration of its branch in Boston, USA, marking a significant step in the company’s global expansion strategy.
Enhancing International Collaboration Networks
The establishment of the Boston branch is expected to significantly enhance VIVA Bio’s international collaboration networks. This move will allow the company to provide comprehensive one-stop CRO-CMC/CDMO services to clients worldwide, covering the entire spectrum from drug discovery and preclinical development to commercial manufacturing.
Global Hub for Seamless Operations
The Boston branch will serve as a crucial hub within Viva Biotech’s global network, seamlessly connecting operations in China, the United States, the United Kingdom, Europe, and other regions. This strategic location will facilitate closer collaboration with international partners and clients, enhancing the company’s ability to deliver high-quality services and support across various stages of drug development and manufacturing.-Fineline Info & Tech
